Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4
Carolyn L. Cummins, Wolfgang Jacobsen, Leslie Z. Benet · Journal of Pharmacology and Experimental Therapeutics · 2002
Cited by 289 works. doi:10.1124/jpet.300.3.1036
Authors
References
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
- The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.
- Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
- Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
- The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
- Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
- Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.